• 1
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
  • 2
    McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768.
  • 3
    Di Marco V, Iacono OL, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. HEPATOLOGY 1999; 30: 157-164.
  • 4
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis e antigen positive chronic hepatitis B. Ann Intern Med 1993; 119: 312-323.
  • 5
    Liaw YF, Lin SM, Chan TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic hepatitis B hepatitis in Asians: a randomized controlled trial. J Hepatol 1994; 20: 175-180.
  • 6
    Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
  • 7
    van Zonneveld M, Hondoop P, Hansen BE, Niesters HGM, Murad SD, de man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. HEPATOLOGY 2004; 39: 804-810.
  • 8
    Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW, and the European Concerted Action on Viral Hepatitis (Eurohep). Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treatment with interferon alfa. HEPATOLOGY 1997; 26: 1338-1342.
  • 9
    Lau DTY, Everhart J, Kliener DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667.
  • 10
    Niederau C, Heintges T, Lange S, Goldmann G, Miederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
  • 11
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. HEPATOLOGY 1999; 29: 971-975.
  • 12
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
  • 13
    Dienstag J, Schiff ER, Wright TL, Perrillo RP, Hann JWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
  • 14
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
  • 15
    Dienstag JL, Cianciara J, Karayalcin S, Kowdley K, Willems B, Plisek S, et al. Durability of serological response after lamivudine treatment of chronic hepatitis B. HEPATOLOGY 2003; 37: 748-755.
  • 16
    Van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424.
  • 17
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. HEPATOLOGY 2000; 32: 803-806.
  • 18
    Chang TT, Shiffman M, Tong M, Marcellin P, Liaw TF, Luengrojanakul P, et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) [Abstract]. J Hepatol 2004; 40(Suppl 1): 126.
  • 19
    Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hung C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
  • 20
    Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Three year study of adefovir dipivoxil (ADV) demonstrates sutained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) [Abstract]. J Hepatol 2004; 40(Suppl 1): 17.
  • 21
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46: 562-568.
  • 22
    Chan HLY, Leung NWY, Hui AY, Wong VWS, Liew CT, Chim AML, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon alfa-2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-250.
  • 23
    Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viraemia? HEPATOLOGY 2001; 34: 1021-1026.
  • 24
    Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. HEPATOLOGY 2000; 32: 626-629.
  • 25
    Chan HLY, Chui AKK, Lau WY, Chan FKL, Wong ML, Tse CH, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-187.
  • 26
    Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus: large-scaled analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-1293.
  • 27
    Chan HLY, Hui AY, Wong ML, Tse AML, Hung LCT, Wong VWS, et al. Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
  • 28
    Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 3729-3734.
  • 29
    Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123-129.
  • 30
    Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
  • 31
    Lau G, Piratvisuth T, Luo X, Marcellin P, Thongasawt S, Cooksley G, et al. Peginterferon alfa-2a (40kD) (PEGASYS) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: Results from a large, multinational study [Abstract]. HEPATOLOGY 2004; 40(Suppl): 171A.
  • 32
    Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Linsay K, Payne J, et al. A randomized controlled trial of interferon alfa-2a alone and after predisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
  • 33
    Lee CM, Ong GY, Lu SN, Wan JH, Liao CA, Tung HD, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37: 669-674.
  • 34
    Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124: 925-932.
  • 35
    Chan HLY, Tsui SKW, Tse CH, Ng EYT, Au TCC, Yuen L, et al. Epidemiological and virological characteristics of two subgroups of genotype C hepatitis B virus. J Infect Dis (in press).
  • 36
    Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
  • 37
    Chan HLY, Tsang SWC, Liew CT, Tse CH, Wong ML, Ching JYL, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-412.
    Direct Link:
  • 38
    Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. HEPATOLOGY 2003; 36: 1408-1415.
  • 39
    Chan HLY, Wong ML, Hui AY, Hung LCT, Chan FKL, Sung JJY. The value of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in chronic hepatitis B. J Clin Microbiol 2003; 41: 4693-4695.
  • 40
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. Long-term follow up after initial response to interferon therapy in patients with HBeAg negative chronic hepatitis B [Abstract]. HEPATOLOGY 2000; 32: 378A.